PBM
ARTV

Propel Bio Management’s Artiva Biotherapeutics ARTV Stock Holding History

Propel Bio Management’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.76M Buy
696,436
+550,067
+376% +$5.01M 3.54% 9
2026
Q1 		$950K Buy
+146,369
New +$724K 0.6% 36

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

Propel Bio Management's ARTV Position: Q2 2026 in Review

Propel Bio Management increased its Artiva Biotherapeutics (ARTV) stake by 376% in Q2 2026, buying an estimated $5.01M and bringing the position to 696,436 shares worth $6.76M. The position accounts for 3.54% of the portfolio, ranked #9.

Propel Bio Management first reported a position in ARTV in Q1 2026 and has held it in 2 quarters since. 65 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

  • Propel Bio Management held 696,436 shares of Artiva Biotherapeutics worth $6.76M as of Q2 2026.
  • Propel Bio Management bought 550,067 Artiva Biotherapeutics shares in Q2 2026, an estimated $5.01M.
  • Artiva Biotherapeutics made up 3.54% of Propel Bio Management's portfolio in Q2 2026, its #9 holding.
  • Propel Bio Management first reported a position in Artiva Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 65 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Propel Bio Management's 13F filing for Q2 2026, filed 13 Aug 2026.